Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia

Am J Physiol Lung Cell Mol Physiol. 2003 Feb;284(2):L333-41. doi: 10.1152/ajplung.00183.2002. Epub 2002 Oct 25.

Abstract

To test the hypothesis that endothelial dysfunction in hyperhomocysteinemia was due to increased levels of nitrotyrosine and matrix metalloproteinase (MMP) activity in response to antagonism of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), cystathionine beta-synthase (CBS) -/+ mice were bred, tail tissue was analyzed for genotype by PCR, and tail vein blood was analyzed for homocysteine (Hcy) by spectrofluorometry. To induce PPAR-alpha, mice were administered 8 microg/ml of ciprofibrate (CF) and grouped: 1) wild type (WT), 2) WT + CF, 3) CBS, 4) CBS + CF (n = 6 in each group). In these four groups of mice, plasma Hcy was 3.0 +/- 0.2, 2.5 +/- 1.2, 15.2 +/- 2.6 (P < 0.05 compared with WT), 11.0 +/- 2.9 micromol/l. Mouse urinary protein was 110 +/- 11, 86 +/- 6, 179 +/- 13, 127 +/- 9 microg.day(-1). kg(-1) by Bio-Rad dye binding assay. Aortic nitrotyrosine was 0.099 +/- 0.012, 0.024 +/- 0.004, 0.132 +/- 0.024 (P < 0.01 compared with WT), 0.05 +/- 0.01 (scan unit) by Western analysis. MMP-2 activity was 0.053 +/- 0.010, 0.024 +/- 0.002, 0.039 +/- 0.009, 0.017 +/- 0.006 (scan unit) by zymography. MMP-9 was specifically induced in CBS -/+ mice and inhibited by CF treatment. Systolic blood pressure (SPB) was 90 +/- 2, 88 +/- 16, 104 +/- 8 (P < 0.05 compared with WT), 96 +/- 3 mmHg. Aortic wall stress [(SPB. radius(2)/wall thickness)/2(radius + wall thickness)] was 10.2 +/- 1.9, 9.7 +/- 0.2, 16.6 +/- 0.8 (P < 0.05 compared with WT), 13.1 +/- 2.1 dyn/cm(2). The results suggest that Hcy increased aortic wall stress by increasing nitrotyrosine and MMP-9 activity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Aorta / enzymology
  • Aorta / pathology
  • Aorta / physiopathology
  • Blood Pressure
  • Clofibric Acid / analogs & derivatives*
  • Clofibric Acid / pharmacology
  • Cystathionine beta-Synthase / genetics
  • Endothelium, Vascular / physiopathology*
  • Enzyme Activation
  • Fibric Acids
  • Genotype
  • Homocysteine / blood
  • Hyperhomocysteinemia / complications
  • Hyperhomocysteinemia / genetics
  • Hyperhomocysteinemia / pathology
  • Hyperhomocysteinemia / physiopathology*
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Mutant Strains / genetics
  • Peroxisome Proliferators / metabolism*
  • Phenotype
  • Proteinuria / etiology
  • Tyrosine / analogs & derivatives*
  • Tyrosine / biosynthesis

Substances

  • Fibric Acids
  • Matrix Metalloproteinase Inhibitors
  • Peroxisome Proliferators
  • Homocysteine
  • 3-nitrotyrosine
  • Tyrosine
  • Clofibric Acid
  • Matrix Metalloproteinases
  • Cystathionine beta-Synthase
  • ciprofibrate